Investors Back iOmx’s Focus On Tumor Immune Evasion
Developing Anti-Immune Evasion Platform
Executive Summary
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022
You may also be interested in...
MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’
MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.